Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HCP2102 in Essential Hypertension
NCT05450601Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HGP2102-1 in essential hypertension, sponsored by Hanmi Pharmaceutical. Started Sep 2022; status: completed.
02
Drugs
HGP2102-1
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT05450601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05450601.